Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of hematological malignancies with poor survival, while treatment options for relapsed or refractory (R/R) disease remain quite limited, with a median progression-free survival of only 3–4 months. Notably, the emergence of innovative therapeutic agents and regimens holds promise for durable responses and improved survival for patients with R/R PTCL. We summarize recent advances in the treatment of R/R PTCL from the 2023 ASH Annual Meeting, highlighting novel agents targeting EZH1/2, JAK1, PI3K, KIR3DL2, CD38/CD3xCD28, or CDK9, as well as therapeutic regimens in combination with stem cell transplantation, immunomodulators, epigenetic modifying agents, or CD30/CD16A bispecific antibodies.

中文翻译：

---

复发或难治性外周 T 细胞淋巴瘤的新药和治疗方案：2023 年 ASH 年会的最新更新


外周 T 细胞淋巴瘤 (PTCL) 是一组异质性血液恶性肿瘤，生存率较差，而复发或难治性 (R/R) 疾病的治疗选择仍然相当有限，中位无进展生存期仅为 3-4 个月。值得注意的是，创新治疗药物和治疗方案的出现有望为 R/R PTCL 患者带来持久缓解并提高生存率。我们总结了 2023 年 ASH 年会上 R/R PTCL 治疗的最新进展，重点介绍了针对 EZH1/2、JAK1、PI3K、KIR3DL2、CD38/CD3xCD28 或 CDK9 的新型药物，以及与干细胞联合的治疗方案移植、免疫调节剂、表观遗传修饰剂或 CD30/CD16A 双特异性抗体。